10-Q · May 11, 2026
Sana Biotechnology, Inc. reported a net loss of $47.2 million for Q1 2026, an improvement from a loss of $49.4 million in the same quarter last year. The company continues to make progress in developing its ex vivo and…
Earnings analysis · 10-Q
SANA earnings analysis
Filed August 10, 2026 · Our reading of the company's report
The latest report
Sana’s Q2 2026 GAAP loss narrowed to -$0.22 per share from -$0.39 in Q2 2025, but the filing provides no revenue, margin, segment, operating cash-flow, or free-cash-flow disclosures in the supplied text. Liquidity was…
Read full summary
Sana’s Q2 2026 GAAP loss narrowed to -$0.22 per share from -$0.39 in Q2 2025, but the filing provides no revenue, margin, segment, operating cash-flow, or free-cash-flow disclosures in the supplied text. Liquidity was $160.5 million, yet management stated that resources may not fund planned operations for at least one year and disclosed substantial doubt about continuing as a going concern. Pipeline prioritization toward SC451 and SG293 may improve resource efficiency, but funding needs, milestone liabilities, clinical uncertainty, manufacturing dependence, and ongoing securities litigation remain significant headwinds.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-0.22
What stood out
-
GAAP Loss Improved Year Over Year
GAAP EPS was -$0.22 in Q2 2026, improving by $0.17 from -$0.39 in Q2 2025 and by $0.05 from -$0.27 implied by the prior quarter’s reported loss trend. The filing does not disclose revenue or margin data.
-
Substantial Liquidity Reserve
Cash, cash equivalents, and marketable securities totaled $160.5 million as of June 30, 2026. The company also reported $103.4 million of marketable securities and $61.3 million of cash, cash equivalents, and restricted cash in its market-risk disclosures.
-
No Variable-Rate Debt
Sana had no debt outstanding subject to interest-rate variability as of June 30, 2026. Management also stated that a hypothetical 10% change in market interest rates would not have had a significant impact on the value of its short-term portfolio.
-
Controls Remained Effective
Disclosure controls and procedures were concluded to be effective at a reasonable assurance level as of June 30, 2026, and the company reported no material change in internal control over financial reporting during the quarter.
-
Pipeline Focus Increased
Sana prioritized development of SC451 and SG293 and suspended development and further internal investment in SC291 and SC262, its two allogeneic cell therapy CAR T programs. The company stated that this prioritization was intended to consolidate resources and reduce operating losses over time.
-
Liability Revaluation Remains Material
The estimated aggregate fair value of Cobalt and Harvard success-payment liabilities was $24.5 million as of June 30, 2026, compared with $19.2 million as of December 31, 2025. The company recorded $7.6 million of expense related to changes in those liabilities during the three months ended June 30, 2026.
What to watch
-
Going-Concern Uncertainty
Management determined that existing capital resources may not be sufficient to fund planned operations for at least one year from the filing date and stated that there is substantial doubt about the company’s ability to continue as a going concern. As of June 30, 2026, liquidity was $160.5 million, but the company expects to require additional funding.
-
Large Milestone Liabilities
Success-payment and contingent-consideration obligations could create substantial cash needs or dilution: Cobalt contingent consideration is up to $500.0 million, the Cobalt success payment is $500.0 million, and Harvard success payments may total up to $175.0 million. The estimated fair value of Cobalt contingent consideration was $150.8 million as of June 30, 2026.
-
Securities Litigation Progressed
The securities class action concerning statements about SC291 and the company’s finances advanced during the quarter: the court granted plaintiffs’ motion to amend on May 21, 2026, a second amended complaint was filed on May 26, 2026, and the proceeding was stayed for 90 days with a joint status report due September 9, 2026.
-
CDMO Capacity Concentration
The company remains dependent on external manufacturing capacity and third parties: it states that it currently relies on CDMOs, that a limited number of CDMOs have the required expertise, and that some CDMOs have limited capacity requiring commitments well in advance. A failure at a single CDMO could delay manufacturing across multiple programs.
-
Novel-Platform Safety Risk
Novel cell-engineering technologies carry significant clinical and regulatory uncertainty. The filing notes that there are no FDA-approved therapeutics derived from pluripotent stem cells and that the FDA has imposed clinical holds on certain products after genomic abnormalities were detected in as few as one patient.
-
AI and Cybersecurity Exposure
The filing adds or expands exposure to evolving artificial-intelligence risks, including potential disclosure of confidential information, third-party intellectual-property claims, inaccurate output, and emerging regulation. It also states that the company has not experienced a material system failure, accident, or security breach to date, but cannot assure that future incidents will be prevented.
Management's outlook
No formal numeric revenue or EPS guidance was provided in the filing. Management states that existing capital resources may not fund planned operations for at least one year from the filing date, despite reporting $160.5 million of cash, cash equivalents, and marketable securities as of June 30, 2026.
Earlier filings 4
10-K · March 3, 2026
The 10-K emphasizes strong clinical progress on two prioritized programs: UP421/SC451 (HIP-modified islet cells for type 1 diabetes) and SG293 (in vivo CAR T), including UP421 demonstrating survival and function at 12…
10-Q · November 6, 2025
Sana reported a smaller Q3 2025 net loss of $42.2M (EPS $(0.16)) versus a net loss of $59.9M (EPS $(0.25)) in Q3 2024, driven by an approximate $18.2M (29.5%) reduction in total operating expenses to $43.5M. Liquidity…
10-Q · August 11, 2025
Sana reported a Q2 2025 GAAP net loss of $93.8M (loss per share $(0.39)), driven by a $44.6M impairment of long-lived assets and changes in success/contingent consideration. Cash and marketable securities totaled $72.7M…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.